With the increasing morbidity and mortality, China's cancer treatment faces serious challenges.
Recently, the data obtained by the reporter from the China Foreign Investment Enterprise Association Drug Development and Development Industry Committee (hereinafter referred to as RDPAC) shows that the accessibility of new Chinese cancer treatment drugs is far less than that of developed countries such as the United States and the United Kingdom. According to statistics, only 6 of the 49 new cancer drugs listed in 2010-2014 are marketed in China for patients. At the same time, the number of cancer-related clinical medical research projects in China is less than one-fifth that of the United States.
Zhang Fangzhi, vice president of the Chinese medicine department of Roche Pharmaceuticals, told reporters that the drug market is different from the automobile industry or the computer industry. It can be listed after being manufactured, but it is a complicated process. On the one hand, in the past, only clinical trials and approvals in China took about 30 months, and last year it was shortened to 8-10 months. On the other hand, in addition to clinical trials, new drug development needs to accept government management, ethics committees and other approvals, while doctors It is not necessarily willing to take time to invest in clinical trials for new drug development.
Colorectal cancer and esophageal cancer are the most burdened
According to data obtained from the RDPAC, according to the 2015 China Cancer Statistics, there were 4.29 million new cancer cases in 2015, accounting for 20% of new global cases and 2.81 million deaths.
"Cancer has become a major disease affecting people's lives." Dixie, CEO of RDPAC, pointed out that cancer is already a major medical burden for Chinese society.
According to a report released by RDPAC, the latest research report shows that colorectal cancer and esophageal cancer have the heaviest burden of per capita visits in urban areas of China, about 10,000 US dollars, followed by lung cancer and stomach cancer patients, which is about 9900 US dollars. The per capita expenditure for liver cancer and breast cancer is about $8,500.
"What is the concept of these figures? This burden is very huge." Wu Yilong, a well-known lung cancer treatment expert and vice president of the Guangdong Provincial People's Hospital, said bluntly. According to statistics, for a country, the average annual expenditure for a family is $8,500. If someone gets lung cancer, it means that the family’s total annual expenditure is gone.
Li Bin (a pseudonym), a domestic pharmaceutical company responsible for regional sales in Sichuan, told reporters that imported drugs can improve the survival of patients. There are no other alternative drugs in China, and the price is naturally high. For example, a molecularly targeted drug that is very effective against gastrointestinal stromal tumors and leukemia, a box of 120 tablets of 24,000 yuan, can eat for 1 month. Although this imported drug has been included in medical insurance in some provinces, patients have to eat for 1 year or 3 years after surgery, and the cost is quite high.
China Extract Powder For Use As Dietary Supplement Extract Powder, Extract Powder Manufacturer
Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.apipepdites.com